ALCAT1 Inhibitors for Mitochondrial Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with mitochondrial dysfunction, such as metabolic diseases, cardiac diseases, and neurological disorders, are inadequate in addressing the underlying mitochondrial issues, particularly due to defective cardiolipin remodeling and oxidative stress.
Innovation Solution
Development of compositions that modulate the expression and activity of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1), including inhibitors that target ALCAT1 to regulate mitochondrial function, structure, and oxidative stress, thereby improving mitochondrial integrity and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for mitochondrial dysfunction diseases, then general symptoms are addressed, but underlying mitochondrial issues caused by defective cardiolipin remodeling and oxidative stress are not resolved
Solution Approach 1:
The patent identifies ALCAT1 as the enzyme responsible for pathological cardiolipin remodeling that generates oxidative stress. By developing specific ALCAT1 inhibitors, the invention converts the harmful oxidative stress pathway into a beneficial target for treatment, blocking the harmful remodelling while preserving normal mitochondrial function.
Solution Approach 2:
The patent introduces ALCAT1 inhibitors as intermediary compounds that mediate between the pathological remodelling process and the desired therapeutic outcome. These inhibitors act as intermediaries to block the harmful enzymatic activity while allowing other essential mitochondrial processes to continue normally.
2Reliability
If ALCAT1 activity is inhibited to reduce oxidative stress, then mitochondrial function is improved, but cardiolipin remodeling process is altered
Solution Approach 1:
The patent applies local quality by selectively targeting ALCAT1 enzyme activity in specific pathological contexts while preserving normal cardiolipin remodeling in healthy tissues. The inhibitors are designed to interfere with the pathological remodelling pathway locally without disrupting essential mitochondrial functions elsewhere.
Solution Approach 2:
The patent changes the parameter of ALCAT1 enzymatic activity through specific inhibitors, thereby altering the cardiolipin composition in a controlled manner. This parameter change redirects the remodelling process from pathological to physiological patterns, improving mitochondrial function while maintaining compositional stability.
3Reliability
If specific ALCAT1 inhibitors are developed to target mitochondrial dysfunction, then treatment effectiveness is improved, but drug development complexity increases
Solution Approach 1:
The patent develops ALCAT1 inhibitors with universal applicability across multiple mitochondrial dysfunction diseases including diabetes, obesity, cardiac diseases, and neurodegenerative disorders. This multi-functionality reduces the need for disease-specific drug development, simplifying the overall process while maintaining high effectiveness across different conditions.
Solution Approach 2:
The patent performs preliminary identification and characterization of ALCAT1 as a therapeutic target before developing specific inhibitors. This preliminary action includes validating the enzyme's role in pathological remodelling and oxidative stress, which streamlines subsequent drug development by establishing a clear mechanistic target and reducing experimental complexity.
Data Source
AI summary
Compositions of modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.